Clinical Trial: A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07786454) titled 'A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder' on Aug. 20.

Brief Summary: This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.

Study Start Date: Oct. 06

Study Type: INTERVENTIONAL

Condition: Generalized Anxiety Disorder

Intervention: DRUG: SEP-363856

Oral tablet

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Otsuka Pharm...